SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
Clin. transl. oncol. (Print)
; 25(9): 2707-2717, sept. 2023. ilus, tab
Article
en En
| IBECS
| ID: ibc-224135
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers (AU)
Palabras clave
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Tumores del Estroma Gastrointestinal
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2023
Tipo del documento:
Article